Assembly Biosciences, Inc. (ASMB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jason A. Okazaki | CEO, President & Director | 1.07M | -- | 1976 |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer | 723.24k | -- | 1972 |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer | 616.94k | -- | -- |
| Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical & Scientific Advisor | 608.55k | -- | 1972 |
| Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board | -- | -- | -- |
| Jeanette M Bjorkquist | Executive Director of Accounting & Treasury | -- | -- | -- |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | -- | -- | -- |
| Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer | -- | -- | -- |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer | -- | -- | 1978 |
| Mr. Thomas E. Rollins | Executive Officer | 472.55k | -- | 1956 |
Assembly Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 65
Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
August 7, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
Assembly Biosciences, Inc. Earnings Date